ORBi: Detailled Reference

Article (Scientific journals)

Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?

Berger, Manon; Lechanteur, Anna; Evrard, Brigitte et al.

2021 • In International Journal of Pharmaceutics

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/261980

DOI
10.1016/j.ijpharm.2021.120851

PubMed
34217823

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Review Manon Berger.pdf

Publisher postprint (7.42 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cancer; Gene delivery; Lipid nanoparticle; pH-sensitive lipid; Cell-penetrating peptide

Abstract :

[en] Over the past two decades, RNA interference has become an extensively studied mechanism to silence gene and treat diseases including cancer. siRNA appears as a promising strategy that could avoid some side effects related to traditional chemotherapy. Considering the weak stability of naked siRNA in blood, vectors like cationic liposomes or Lipid Nanoparticles (LNPs) are widely used to carry and protect siRNA until it reaches the tumor targeted. Despite extensive research, only three RNAi drugs are currently approved by the Food and Drug Administration, including only one LNP formulation of siRNA to treat hereditary ATTR amyloidosis. This shows the difficulty of lipoplexes clinical translation, in particular in cancer therapy. To overcome the lipoplexes limitations, searches are made on innovative lipoplexes formulations with enhanced siRNA efficacy. The present review is focusing on the recent use of pH-sensitive lipids, peptides and cell-penetrating peptides or polymers. The incorporation of some of these components in the lipoplex formulation induces a fusogenic property or an enhanced endosomal escape, an enhanced cellular uptake, an enhanced tumor targeting, an improved stability in the blood stream …These innovations appear critical to obtain an efficient siRNA accumulation in tumor cells with effective antitumor effect considering the complex tumor environment.

Research Center/Unit :

Center for Interdisciplinary Research on Medicines (CIRM)

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Berger, Manon ; Université de Liège - ULiège > Département de pharmacie > Développement de nanomédicaments

Lechanteur, Anna ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique

Piel, Géraldine ; Université de Liège - ULiège > Département de pharmacie > Développement de nanomédicaments

Language :

English

Title :

Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?

Publication date :

July 2021

Journal title :

International Journal of Pharmaceutics

ISSN :

0378-5173

eISSN :

1873-3476

Publisher :

Elsevier, Netherlands

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

ARC for Lipegalt project

Available on ORBi :

since 12 July 2021

Statistics

Number of views

78 (25 by ULiège)

Number of downloads

7 (6 by ULiège)

More statistics

Scopus citations^®

25

Scopus citations^®
without self-citations

23

OpenCitations

10

OpenAlex citations

28

Bibliography

Abd Elwakil, M.M., Khalil, I.A., Elewa, Y.H.A., Kusumoto, K., Sato, Y., Shobaki, N., Kon, Y., Harashima, H., Lung-endothelium-targeted nanoparticles based on a pH-sensitive lipid and the GALA peptide enable robust gene silencing and the regression of metastatic lung cancer. Adv. Funct. Mater., 29, 2019, 10.1002/adfm.201807677.
Abu Lila, A.S., Nawata, K., Shimizu, T., Ishida, T., Kiwada, H., Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharm. 456 (2013), 235–242, 10.1016/j.ijpharm.2013.07.059.
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S.W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., Nejati-Koshki, K., Liposome: Classification, preparation, and applications. Nanoscale Res. Lett., 8, 2013, 102, 10.1186/1556-276X-8-102.
Alnylam, 2020a. GIVLAARI US Prescribing information [WWW Document]. URL https://www.alnylam.com/wp-content/uploads/pdfs/GIVLAARI-Prescribing-Information.pdf. Accessed December 2020.
Alnylam, 2020b. OXLUMO US Prescribing information [WWW Document]. URL https://www.alnylam.com/wp-content/uploads/pdfs/OXLUMO-Prescribing-Information.pdf. Accessed December 2020.
Ambegia, E., Ansell, S., Cullis, P., Heyes, J., Palmer, L., MacLachlan, I., Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta - Biomembr. 1669 (2005), 155–163, 10.1016/j.bbamem.2005.02.001.
Bakhiet, M., Taurin, S., SARS-CoV-2: targeted managements and vaccine development. Cytokine Growth Factor Rev., 2020, 10.1016/j.cytogfr.2020.11.001.
Bellefroid, C., Lechanteur, A., Evrard, B., Piel, G., Lipid gene nanocarriers for the treatment of skin diseases: Current state-of-the-art. Eur. J. Pharm. Biopharm. 137 (2019), 95–111, 10.1016/j.ejpb.2019.02.012.
Bisso, S., Leroux, J.C., Nanopharmaceuticals: A focus on their clinical translatability. Int. J. Pharm., 578, 2020, 10.1016/j.ijpharm.2020.119098.
Bromma, K., Rieck, K., Kulkarni, J., O'Sullivan, C., Sung, W., Cullis, P., Schuemann, J., Chithrani, D.B., Use of a lipid nanoparticle system as a Trojan horse in delivery of gold nanoparticles to human breast cancer cells for improved outcomes in radiation therapy. Cancer Nanotechnol., 10, 2019, 10.1186/s12645-019-0046-z.
Buyens, K., De Smedt, S.C., Braeckmans, K., Demeester, J., Peeters, L., Van Grunsven, L.A., De Mollerat, Du., Jeu, X., Sawant, R., Torchilin, V., Farkasova, K., Ogris, M., Sanders, N.N., Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J. Control. Release 158 (2012), 362–370, 10.1016/j.jconrel.2011.10.009.
Campani, V., Salzano, G., Lusa, S., de Rosa, G., Lipid nanovectors to deliver RNA oligonucleotides in cancer. Nanomaterials, 6, 2016, 10.3390/nano6070131.
Chen, L., Luo, Y., Liu, T., Yuan, Y., Gu, H., Yang, Y., Li, L., Tan, L., Label-free electrochemical immunoassay of Bcl-2 protein expression on tumor cells. Talanta 132 (2015), 479–485, 10.1016/j.talanta.2014.09.047.
Chen, Z., Zhang, T., Wu, B., Zhang, X., Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. Int. J. Nanomed. 11 (2016), 991–1002, 10.2147/IJN.S101872.
Ciccarelli, C., Di Rocco, A., Gravina, G.L., Mauro, A., Festuccia, C., Del Fattore, A., Berardinelli, P., De Felice, F., Musio, D., Bouché, M., Tombolini, V., Zani, B.M., Marampon, F., Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. J. Cancer Res. Clin. Oncol. 144 (2018), 1685–1699, 10.1007/s00432-018-2696-3.
Cullis, P.R., Hope, M.J., Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 25 (2017), 1467–1475, 10.1016/j.ymthe.2017.03.013.
Cupido, A.J., Kastelein, J.J.P., Inclisiran for the treatment of hypercholesterolaemia: Implications and unanswered questions from the ORION trials. Cardiovasc. Res. 116 (2020), E136–E139, 10.1093/cvr/cvaa212.
Dan, N., Danino, D., Structure and kinetics of lipid-nucleic acid complexes. Adv. Colloid Interface Sci. 205 (2014), 230–239, 10.1016/j.cis.2014.01.013.
David, S., Pitard, B., Benoît, J.P., Passirani, C., Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62 (2010), 100–114, 10.1016/j.phrs.2009.11.013.
Derakhshankhah, H., Jafari, S., Cell penetrating peptides: A concise review with emphasis on biomedical applications. Biomed. Pharmacother. 108 (2018), 1090–1096, 10.1016/j.biopha.2018.09.097.
Di Matteo, P., Curnis, F., Longhi, R., Colombo, G., Sacchi, A., Crippa, L., Protti, M.P., Ponzoni, M., Toma, S., Corti, A., Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol. Immunol. 43 (2006), 1509–1518, 10.1016/j.molimm.2005.10.009.
Endo, R., Nakamura, T., Kawakami, K., Sato, Y., Harashima, H., The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy. Sci. Rep., 9, 2019, 11335, 10.1038/s41598-019-47799-w.
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., Potent and specific genetic interference by double-strandedRNAin Caenorhabditis elegans. Nature 391 (1998), 806–811.
Fontanellas, A., Ávila, M.A., Anderson, K.E., Deybach, J.C., Current and innovative emerging therapies for porphyrias with hepatic involvement. J. Hepatol. 71 (2019), 422–433, 10.1016/j.jhep.2019.05.003.
Garu, A., Moku, G., Gulla, S.K., Pramanik, D., Majeti, B.K., Karmali, P.P., Shaik, H., Sreedhar, B., Chaudhuri, A., Examples of tumor growth inhibition properties of liposomal formulations of pH-sensitive histidinylated cationic amphiphiles. ACS Biomater. Sci. Eng. 1 (2015), 646–655, 10.1021/acsbiomaterials.5b00025.
Guo, P., Yang, J., Jia, D., Moses, M.A., Auguste, D.T., ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics 6 (2016), 1–13, 10.7150/thno.12167.
Hamoudi, M.C., Henry, E., Zerrouk, N., Scherman, D., Arnaud, P., Deprez, E., Escriou, V., Enhancement of siRNA lipid-based vector stability and siRNA integrity in human serum with addition of anionic polymer adjuvant. J. Drug Deliv. Sci. Technol. 26 (2015), 1–9, 10.1016/j.jddst.2015.01.001.
Hattori, Y., Tamaki, K., Ozaki, K. ichi, Kawano, K., Onishi, H., 2019. Optimized combination of cationic lipids and neutral helper lipids in cationic liposomes for siRNA delivery into the lung by intravenous injection of siRNA lipoplexes. J. Drug Deliv. Sci. Technol. 52, 1042–1050. https://doi.org/10.1016/j.jddst.2019.06.016.
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., Liang, X.J., Therapeutic siRNA: state of the art. Signal Transduct. Target. Ther., 5, 2020, 10.1038/s41392-020-0207-x.
Hu, Y.B., Dammer, E.B., Ren, R.J., Wang, G., The endosomal-lysosomal system: From acidification and cargo sorting to neurodegeneration. Transl. Neurodegener., 4, 2015, 10.1186/s40035-015-0041-1.
Jayaraman, M., Ansell, S.M., Mui, B.L., Tam, Y.K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J.K., Rajeev, K.G., Hafez, I.M., Akinc, A., Maier, M.A., Tracy, M.A., Cullis, P.R., Madden, T.D., Manoharan, M., Hope, M.J., Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51 (2012), 8529–8533, 10.1002/anie.201203263.
Jee, H., Nwagwu, C., Anyim, O., Ekweremadu, C., Kim, S., COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int. Immunopharmacol., 90, 2021, 107247, 10.1016/j.intimp.2020.107247.
Jyotsana, N., Sharma, A., Chaturvedi, A., Budida, R., Scherr, M., Kuchenbauer, F., Lindner, R., Noyan, F., Sühs, K.W., Stangel, M., Grote-Koska, D., Brand, K., Vornlocher, H.P., Eder, M., Thol, F., Ganser, A., Humphries, R.K., Ramsay, E., Cullis, P., Heuser, M., Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Ann. Hematol. 98 (2019), 1905–1918, 10.1007/s00277-019-03713-y.
Kapoor, M., Burgess, D.J., Patil, S.D., Physicochemical characterization techniques for lipid based delivery systems for siRNA. Int. J. Pharm. 427 (2012), 35–57, 10.1016/j.ijpharm.2011.09.032.
Kc, R., Thapa, B., Ubeda, A., Jiang, X., Uludaǧ, H., BCR-Abl silencing by siRNA: A potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy. Stem Cells Dev. 28 (2019), 734–744, 10.1089/scd.2018.0196.
Kiaie, S.H., Mojarad-Jabali, S., Khaleseh, F., Allahyari, S., Taheri, E., Zakeri-Milani, P., Valizadeh, H., Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives. Int. J. Pharm., 581, 2020, 119269, 10.1016/j.ijpharm.2020.119269.
Kierstead, P.H., Okochi, H., Venditto, V.J., Chuong, T.C., Kivimae, S., Fréchet, J.M.J., Szoka, F.C., The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J. Control. Release 213 (2015), 1–9, 10.1016/j.jconrel.2015.06.023.
Kon, E., Hazan-Halevy, I., Rosenblum, D., Cohen, N., Chatterjee, S., Veiga, N., Raanani, P., Bairey, O., Benjamini, O., Nagler, A., Peer, D., Resveratrol enhances mrna and sirna lipid nanoparticles primary CLL cell transfection. Pharmaceutics 12 (2020), 1–14, 10.3390/pharmaceutics12060520.
Kulkarni, J.A., Darjuan, M.M., Mercer, J.E., Chen, S., Van Der Meel, R., Thewalt, J.L., Tam, Y.Y.C., Cullis, P.R., On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano 12 (2018), 4787–4795, 10.1021/acsnano.8b01516.
Kumar, V.V., Pichon, C., Refregiers, M., Guerin, B., Midoux, P., Chaudhuri, A., Single histidine residue in head-group region is sufficient to impart remarkable gene transfection properties to cationic lipids: Evidence for histidine-mediated membrane fusion at acidic pH. Gene Ther. 10 (2003), 1206–1215, 10.1038/sj.gt.3301979.
Kumar, Y., Kuche, K., Swami, R., Katiyar, S.S., Chaudhari, D., Katare, P.B., Banerjee, S.K., Jain, S., Exploring the potential of novel pH sensitive lipoplexes for tumor targeted gene delivery with reduced toxicity. Int. J. Pharm., 573, 2020, 118889, 10.1016/j.ijpharm.2019.118889.
Kusumoto, K., Akita, H., Ishitsuka, T., Matsumoto, Y., Nomoto, T., Furukawa, R., El-Sayed, A., Hatakeyama, H., Kajimoto, K., Yamada, Y., Kataoka, K., Harashima, H., Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano 7 (2013), 7534–7541, 10.1021/nn401317t.
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., Piel, G., PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness. Eur. J. Pharm. Sci. 93 (2016), 493–503, 10.1016/j.ejps.2016.08.058.
Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., Piel, G., Cationic liposomes carrying siRNA: Impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape. Nanomaterials, 8, 2018, 10.3390/nano8050270.
Lee, H.Y., Mohammed, K.A., Nasreen, N., Nanoparticle-based targeted gene therapy for lung cancer. Am. J. Cancer Res. 6 (2016), 1118–1134.
Leite Nascimento, T., Hillaireau, H., Vergnaud, J., Rivano, M., Deloménie, C., Courilleau, D., Arpicco, S., Suk, J.S., Hanes, J., Fattal, E., Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. Int. J. Pharm. 514 (2016), 103–111, 10.1016/j.ijpharm.2016.06.125.
Li, J., Xue, S., Mao, Z.W., Nanoparticle delivery systems for siRNA-based therapeutics. J. Mater. Chem. B 4 (2016), 6620–6639, 10.1039/c6tb01462c.
Lin, P.J.C., Tam, Y.K., Cullis, P.R., Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer. Clin. Lipidol. 9 (2014), 317–331, 10.2217/clp.14.27.
Lin, W., Xie, X., Yang, Yanfang, Liu, Hui, Fu, X., Chen, Y., Liu, Hong, Yang, Yang, Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands. J. Pharm. Pharmacol. 67 (2015), 1215–1231, 10.1111/jphp.12425.
Lipardi, C., Wei, Q., Paterson, B.M., RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell 107 (2001), 297–307, 10.1016/S0092-8674(01)00537-2.
Litzinger, D.C., Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo. J. Liposome Res. 7 (1997), 51–61, 10.3109/08982109709035481.
Liu, C., Zhang, L., Zhu, W., Guo, R., Sun, H., Chen, X., Deng, N., Barriers and strategies of cationic liposomes for cancer gene therapy. Mol. Ther. Methods Clin. Dev. 18 (2020), 751–764, 10.1016/j.omtm.2020.07.015.
Lucey, B.P., Nelson-Rees, W.A., Hutchins, G.M., Henrietta Lacks, HeLa cells, and cell culture contamination. Arch. Pathol. Lab. Med. 133 (2009), 1463–1467, 10.1043/1543-2165-133.9.1463.
Lv, H., Zhang, S., Wang, B., Cui, S., Yan, J., Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114 (2006), 100–109, 10.1016/j.jconrel.2006.04.014.
Madkour, L.H., 2019. Chapter 18 - Biological barriers to cancer drug delivery, efficacy and cancer models. In: Nucleic Acids as Gene Anticancer Drug Delivery Therapy. pp. 359–423. https://doi.org/10.1016/b978-0-12-819777-6.00018-4.
Met, Ö., Wang, M., Pedersen, A.E., Nissen, M.H., Buus, S., Claesson, M.H., The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 231 (2006), 247–256, 10.1016/j.canlet.2005.02.005.
Midoux, P., Pichon, C., Yaouanc, J.J., Jaffrès, P.A., Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157 (2009), 166–178, 10.1111/j.1476-5381.2009.00288.x.
Nagase, K., Hasegawa, M., Ayano, E., Maitani, Y., Kanazawa, H., Effect of polymer phase transition behavior on temperature-responsive polymer-modified liposomes for siRNA transfection. Int. J. Mol. Sci., 20, 2019, 10.3390/ijms20020430.
Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kelin, A.V., Milstein, S., Taneja, N., Oshea, J., Shaikh, S., Zhang, L., Van Der Sluis, R.J., Jung, M.E., Akinc, A., Hutabarat, R., Kuchimanchi, S., Fitzgerald, K., Zimmermann, T., Van Berkel, T.J.C., Maier, M.A., Rajeev, K.G., Manoharan, M., Multivalent N -acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961, 10.1021/ja505986a.
Nakamura, T., Kuroi, M., Fujiwara, Y., Warashina, S., Sato, Y., Harashima, H., Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Sci. Rep., 6, 2016, 10.1038/srep37849.
NIH U.S. National Library of Medicine, 2019a. Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma [WWW Document]. URL https://clinicaltrials.gov/ct2/show/NCT02191878. Accessed June 2021.
NIH U.S. National Library of Medicine, 2019b. A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients [WWW Document]. URL https://clinicaltrials.gov/ct2/show/NCT01262235. Accessed June 2021.
NIH U.S. National Library of Medicine, n.d. ClinicalTrials.gov database [WWW Document]. URL https://clinicaltrials.gov/ct2/results?cond=Cancer&term=sirna&cntry=&state=&city=&dist=. Accessed April 2020.
Obeid, M.A., Tate, R.J., Mullen, A.B., Ferro, V.A., 2018. Lipid-based nanoparticles for cancer treatment, in: Lipid Nanocarriers for Drug Targeting. Elsevier Inc., pp. 313–359. https://doi.org/10.1016/B978-0-12-813687-4.00008-6.
Ozpolat, B., Sood, A.K., Lopez-Berestein, G., Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 66 (2014), 110–116, 10.1016/j.addr.2013.12.008.
Pai, S.I., Lin, Y.Y., Macaes, B., Meneshian, A., Hung, C.F., Wu, T.C., Prospects of RNA interference therapy for cancer. Gene Ther. 13 (2006), 464–477, 10.1038/sj.gt.3302694.
Pal Singh, P., Vithalapuram, V., Metre, S., Kodipyaka, R., Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review. J. Liposome Res. 30 (2020), 313–335, 10.1080/08982104.2019.1652645.
Palchetti, S., Colapicchioni, V., Digiacomo, L., Caracciolo, G., Pozzi, D., Capriotti, A.L., La Barbera, G., Laganà, A., The protein corona of circulating PEGylated liposomes. Biochim. Biophys. Acta - Biomembr. 1858 (2016), 189–196, 10.1016/j.bbamem.2015.11.012.
Park, K.S., Sun, X., Aikins, M.E., Moon, J.J., Non-viral COVID-19 vaccine delivery systems. Adv. Drug Deliv. Rev. 169 (2021), 137–151, 10.1016/j.addr.2020.12.008.
Raucher, D., Ryu, J.S., Cell-penetrating peptides: Strategies for anticancer treatment. Trends Mol. Med. 21 (2015), 560–570, 10.1016/j.molmed.2015.06.005.
Reddy, T.L., Garikapati, K.R., Reddy, S.G., Reddy, B.V.S., Yadav, J.S., Bhadra, U., Bhadra, M.P., Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma. Sci. Rep., 6, 2016, 10.1038/srep35223.
Regberg, J., Srimanee, A., Langel, Ü., Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals 5 (2012), 991–1007, 10.3390/ph5090991.
Rezaee, M., Oskuee, R.K., Nassirli, H., Malaekeh-Nikouei, B., Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. J. Control. Release 236 (2016), 1–14, 10.1016/j.jconrel.2016.06.023.
Rietwyk, S., Peer, D., Next-generation lipids in RNA interference therapeutics. ACS Nano 11 (2017), 7572–7586, 10.1021/acsnano.7b04734.
Rüger, J., Ioannou, S., Castanotto, D., Stein, C.A., Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017–2019. Trends Pharmacol. Sci. 41 (2020), 27–41, 10.1016/j.tips.2019.10.009.
Ruoslahti, E., Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 110–111 (2017), 3–12, 10.1016/j.addr.2016.03.008.
Sakurai, Y., Hada, T., Yamamoto, S., Kato, A., Mizumura, W., Harashima, H., Remodeling of the extracellular matrix by endothelial cell-targeting siRNA improves the EPR-based delivery of 100 nm particles. Mol. Ther. 24 (2016), 2090–2099, 10.1038/mt.2016.178.
Sakurai, Y., Hatakeyama, H., Akita, H., Harashima, H., Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 sirna in human renal cell carcinomas. Mol. Pharm. 11 (2014), 2713–2719, 10.1021/mp500245z.
Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Harashima, H., Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol. Ther. 21 (2013), 1195–1203, 10.1038/mt.2013.57.
Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, K., Harashima, H., RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J. Control. Release 173 (2014), 110–118, 10.1016/j.jconrel.2013.10.003.
Samaridou, E., Heyes, J., Lutwyche, P., Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv. Drug Deliv. Rev. 154–155 (2020), 37–63, 10.1016/j.addr.2020.06.002.
Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., Longacre, M., Cancer development, progression, and therapy: An epigenetic overview. Int. J. Mol. Sci. 14 (2013), 21087–21113, 10.3390/ijms141021087.
Sato, Y., Hashiba, K., Sasaki, K., Maeki, M., Tokeshi, M., Harashima, H., Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J. Control. Release 295 (2019), 140–152, 10.1016/j.jconrel.2019.01.001.
Sato, Y., Hatakeyama, H., Hyodo, M., Harashima, H., Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. Mol. Ther. 24 (2016), 788–795, 10.1038/mt.2015.222.
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., Harashima, H., A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release 163 (2012), 267–276, 10.1016/j.jconrel.2012.09.009.
Sato, Y., Nakamura, T., Yamada, Y., Harashima, H., Development of a multifunctional envelope-type nano device and its application to nanomedicine. J. Control. Release 244 Part B, 2016, 194–204, 10.1016/j.jconrel.2016.06.042.
Sau, S., Tatiparti, K., Alsaab, H.O., Kashaw, S.K., Iyer, A.K., A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy. Drug Discov. Today 23 (2018), 1344–1356, 10.1016/j.drudis.2018.03.003.
Scherman, D., Rousseau, A., Bigey, P., Escriou, V., Genetic pharmacology: Progresses in siRNA delivery and therapeutic applications. Gene Ther. 24 (2017), 151–156, 10.1038/gt.2017.6.
Senapati, D., Patra, B.C., Kar, A., Chini, D.S., Ghosh, S., Patra, S., Bhattacharya, M., Promising approaches of small interfering RNAs (siRNAs) mediated cancer gene therapy. Gene, 719, 2019, 144071, 10.1016/j.gene.2019.144071.
Shim, G., Kim, M.G., Park, J.Y., Oh, Y.K., Application of cationic liposomes for delivery of nucleic acids. Asian J. Pharm. Sci. 8 (2013), 72–80, 10.1016/j.ajps.2013.07.009.
Shimizu, T., Abu Lila, A.S., Fujita, R., Awata, M., Kawanishi, M., Hashimoto, Y., Okuhira, K., Ishima, Y., Ishida, T., A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Eur. J. Pharm. Biopharm. 127 (2018), 142–149, 10.1016/j.ejpb.2018.02.019.
Smith, S.A., Selby, L.I., Johnston, A.P.R., Such, G.K., The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery. Bioconjug. Chem. 30 (2019), 263–272, 10.1021/acs.bioconjchem.8b00732.
Son, K., Ueda, M., Taguchi, K., Maruyama, T., Takeoka, S., Ito, Y., Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J. Control. Release 322 (2020), 209–216, 10.1016/j.jconrel.2020.03.022.
Spänkuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., Strebhardt, K., Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94 (2002), 1863–1877, 10.1093/jnci/94.24.1863.
Subhan, M.A., Torchilin, V.P., siRNA based drug design, quality, delivery and clinical translation. Nanomedicine Nanotechnology. Biol. Med., 29, 2020, 102239, 10.1016/j.nano.2020.102239.
Subhan, M.A., Torchilin, V.P., Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl. Res. 214 (2019), 62–91, 10.1016/j.trsl.2019.07.006.
Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., Gounder, M.M., Falzone, R., Harrop, J., White, A.C.S., Toudjarska, I., Bumcrot, D., Meyers, R.E., Hinkle, G., Svrzikapa, N., Hutabarat, R.M., Clausen, V.A., Cehelsky, J., Nochur, S.V., Gamba-Vitalo, C., Vaishnaw, A.K., Sah, D.W.Y., Gollob, J.A., Burris, H.A., First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3 (2013), 406–417, 10.1158/2159-8290.CD-12-0429.
Tagalakis, A.D., He, L., Saraiva, L., Gustafsson, K.T., Hart, S.L., Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 32 (2011), 6302–6315, 10.1016/j.biomaterials.2011.05.022.
Tam, Y.Y.C., Chen, S., Cullis, P.R., Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5 (2013), 498–507, 10.3390/pharmaceutics5030498.
The World Health Organization, 2018. Cancer [WWW Document]. Fact sheets. URL https://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed April 2020.
Titze-de-Almeida, R., David, C., Titze-de-Almeida, S.S., The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharm. Res. 34 (2017), 1339–1363, 10.1007/s11095-017-2134-2.
Torchilin, V., Levchenko, T., Whiteman, K., Yaroslavov, A., Tsatsakis, A., Rizos, A., Michailova, E., Shtilman, M., 2001. Amphiphilic poly-N-vinylpyrrolidones: Biomaterials 22, 3035–3044. https://doi.org/10.1016/s0142-9612(01)00050-3.
Verbeke, R., Lentacker, I., De Smedt, S.C., Dewitte, H., The dawn of mRNA vaccines: The COVID-19 case. J. Control. Release 333 (2021), 511–520, 10.1016/j.jconrel.2021.03.043.
Viricel, W., Mbarek, A., Leblond, J., Switchable lipids: Conformational change for fast pH-triggered cytoplasmic delivery. Angew. Chemie - Int. Ed. 54 (2015), 12743–12747, 10.1002/anie.201504661.
Viricel, W., Poirier, S., Mbarek, A., Derbali, R.M., Mayer, G., Leblond, J., Cationic switchable lipids: PH-triggered molecular switch for siRNA delivery. Nanoscale 9 (2017), 31–36, 10.1039/c6nr06701h.
Vivès, E., Schmidt, J., Pèlegrin, A., Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta - Rev. Cancer 1786 (2008), 126–138, 10.1016/j.bbcan.2008.03.001.
Wang, J., Ayano, E., Maitani, Y., Kanazawa, H., Enhanced cellular uptake and gene silencing activity of siRNA using temperature-responsive polymer-modified liposome. Int. J. Pharm. 523 (2017), 217–228, 10.1016/j.ijpharm.2017.03.035.
Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., Harashima, H., A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. J. Control. Release 225 (2016), 183–191, 10.1016/j.jconrel.2016.01.042.
Whitehead, K.A., Langer, R., Anderson, D.G., Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138, 10.1038/nrd2742.
Xia, Y., Tian, J., Chen, X., Effect of surface properties on liposomal siRNA delivery. Biomaterials 79 (2016), 56–68, 10.1016/j.biomaterials.2015.11.056.
Xiang, B., Jia, X.L., Qi, J.L., Yang, L.P., Sun, W.H., Yan, X., Yang, S.K., Cao, D.Y., Du, Q., Qi, X.R., Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int. J. Nanomedicine 12 (2017), 2385–2405, 10.2147/IJN.S129574.
Xu, H., Wang, K.Q., Deng, Y.H., Chen, D.W., Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31 (2010), 4757–4763, 10.1016/j.biomaterials.2010.02.049.
Xu, J., Khan, A.R., Fu, M., Wang, R., Ji, J., Zhai, G., Cell-penetrating peptide: a means of breaking through the physiological barriers of different tissues and organs. J. Control. Release 309 (2019), 106–124, 10.1016/j.jconrel.2019.07.020.
Yang, Y., Yang, Y.F., Xie, X.Y., Wang, Z.Y., Gong, W., Zhang, H., Li, Y., Yu, F.L., Li, Z.P., Mei, X.G., Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. Biomaterials 48 (2015), 84–96, 10.1016/j.biomaterials.2015.01.030.
Yang, Yanfang, Xie, X., Xu, X., Xia, X., Wang, H., Li, L., Dong, W., Ma, P., Yang, Yang, Liu, Y., Mei, X., Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy. Colloids Surfaces B Biointerfaces 146 (2016), 607–615, 10.1016/j.colsurfb.2016.07.002.
Yao, Y., Su, Z., Liang, Y., Zhang, N., pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int. J. Nanomedicine 10 (2015), 6185–6198, 10.2147/IJN.S90524.
Yao, Y., Wang, T., Liu, Y., Zhang, N., Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. Artif. Cells, Nanomed. Biotechnol. 47 (2019), 1374–1383, 10.1080/21691401.2019.1596943.
Yingchoncharoen, P., Kalinowski, D.S., Richardson, D.R., Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol. Rev. 68 (2016), 701–787, 10.1124/pr.115.012070.
Youngren-Ortiz, S.R., Gandhi, N.S., España-Serrano, L., Chougule, M.B., Aerosol delivery of siRNA to the lungs. Part 2: Nanocarrier-based delivery systems. KONA Powder Part. J. 34 (2017), 44–69, 10.14356/kona.2017005.
Younis, M.A., Khalil, I.A., Abd Elwakil, M.M., Harashima, H., A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Mol. Pharm. 16 (2019), 4031–4044, 10.1021/acs.molpharmaceut.9b00738.
Yu, M.Z., Pang, W.H., Yang, T., Wang, J.C., Wei, L., Qiu, C., Wu, Y.F., Liu, W.Z., Wei, W., Guo, X.Y., Zhang, Q., Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur. J. Pharm. Sci. 92 (2016), 39–48, 10.1016/j.ejps.2016.06.020.
Zhang, R., Wang, S. Bin, Chen, A.Z., Chen, W.G., Liu, Y.G., Wu, W.G., Kang, Y.Q., Ye, S.F., Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy. J. Biomater. Appl. 30 (2015), 351–360, 10.1177/0885328215579297.
Zhang, S., Zhao, B., Jiang, H., Wang, B., Ma, B., Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 123 (2007), 1–10, 10.1016/j.jconrel.2007.07.016.
Zhi, D., Zhao, Y., Cui, S., Chen, H., Zhang, S., Conjugates of small targeting molecules to non-viral vectors for the mediation of siRNA. Acta Biomater. 36 (2016), 21–41, 10.1016/j.actbio.2016.03.048.
Tebes, S.J., Kruk, P.A., The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. Gynecol. Oncol. 99 (2005), 736–741, 10.1016/j.ygyno.2005.08.031.

Similar publications